zona pellucida like domain containing 1Genealiases: []
Q-omics provides the consensus-scored ZPLD1 profile across patient tissues and cancer cell-line models. ZPLD1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, ZPLD1 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, ZPLD1 RNA expression shows 12,485 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight PAAD, HNSC, and TGCT as cancer lineages where ZPLD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZPLD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZPLD1 survival associations across molecular data types. ZPLD1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZPLD1 RNA expression–survival associations across cancer types. High ZPLD1 expression shows unfavorable associations in PAAD, KIRC, KIRP, CESC and BLCA, but favorable associations in SKCM. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for ZPLD1 RNA expression.
This table summarizes ZPLD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZPLD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZPLD1 shows lower tumor expression in KICH and higher tumor expression in HNSC, LUAD, BRCA, BLCA and LUSC. The HNSC box plot shows higher ZPLD1 RNA expression in tumor versus normal tissue (log2 FC = +0.483, t-test p < 0.001).
This table shows molecular features associated with ZPLD1 in patient tissues and cancer cell lines. In patient samples, ZPLD1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ZPLD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SOFT_TISSUE.
